A case study of an adverse drug reaction caused by long term use of proton pump inhibitors

Swetha Sathish Kumar; Sivani Ravindran; Merin Levy Philips; Syaam Ganesh B.

doi:10.18203/2319-2003.ijbcp20233200

Authors

Swetha Sathish Kumar Department of Pharmacy Practice, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, New Siddhapur, Coimbatore, Tamil Nadu, India
Sivani Ravindran Department of Pharmacy Practice, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, New Siddhapur, Coimbatore, Tamil Nadu, India
Merin Levy Philips Department of Pharmacy Practice, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, New Siddhapur, Coimbatore, Tamil Nadu, India
Syaam Ganesh B. Department of Medicine, Raja Rajeshwari Medical College and Hospital, Mysore Road Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20233200

Keywords:

Hypomagnesemia, Hypocalcemia, Supraventricular tachycardia, PPI, Histamine 2 receptor antagonist

Abstract

Proton pump inhibitors (PPI) are the class of drugs used to treat a wide variety of disorders related to the stomach's acid production. Although it is considered safe for short term use, reports revealed that many serious life-threatening adverse reactions occurred from long term use. Here we report a case of hypomagnesemia and hypocalcemia induced by long-term use of PPIs in a patient with crest syndrome. From his past history, it was revealed that he was on pantoprazole 40 mg for more than 3 months. While he was admitted here for other complaints, we were able to discover that he had hypomagnesemia defined by low magnesium level of 1.3 mg/dL. As a consequence, he also showed signs of hypocalcemia with a low calcium level of 7 mg/dL. A peculiar complaint seen in this patient was three episodes of supraventricular tachycardia which is the most common cardiac manifestations of hypomagnesemia. As a conclusion, hypomagnesemia can sometimes be asymptomatic and cause unspecific and serious manifestations such as asthenia, paresthesia’s, seizures, arrhythmias, and cardiac arrest. Hence routine monitoring of serum magnesium and calcium levels should be made mandatory in practice for patients on long term use of PPI. Besides, it should be kept in mind that interchanging PPI class with histamine 2 receptor antagonist or fitful use of PPI may not cause hypomagnesemia.

Metrics

Metrics Loading ...

References

Yibirin M, Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse Effects Associated with Proton Pump Inhibitor Use. Cureus. 2021;13(1):e12759.

Freedberg DE, Kim LS, Yu-Xiao Y. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152(4):706-15.

Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol. 2018;123(2):114-21.

Low ASL, Lal S, Farrell AJ, Herrick AL. Profound hypomagnesaemia causing symptomatic hypocalcaemia-an underdiagnosed and potentially life-threatening problem in systemic sclerosis? Rheumatology. 2014;53(4):767-9.

Nassar M, Ghernautan V, Nso N, Nyabera A, Castillo FC, Tu W et al. Gastrointestinal involvement in systemic sclerosis: An updated review. Medicine (Baltimore). 2022;101(45):e31780.

Matsuyama J, Tsuji K, Doyama H, Kim F, Takeda Y, Kito Y et al. Hypomagnesemia associated with a proton pump inhibitor. Intern Med. 2012;51(16):2231-4.

Toh JW, Ong E, Wilson R. Hypomagnesaemia associated with long-term use of proton pump inhibitors. Gastroenterol Rep (Oxf). 2015;3(3):243-53.

Noronha JL, Matuschak GM. Magnesium in critical illness: metabolism, assessment and treatment. Intensive Care Med. 2002;28:667-79.

Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol. 2011;27:180-85.

Efstratiadis G, Sarigianni M, Gougourelas I. Hypomagnesemia and cardiovascular system. Hippokratia. 2006;10(4):147-52.

Perez MO, Neves EF, Bortolai CB, Sampaio-Barros PD, Andrade DC, Seguro LP. Hypomagnesaemia and hypocalcaemia in a patient with systemic sclerosis: role of proton pump inhibitors. Clin Exp Rheumatol. 2014;32(6-86):S-225-7.

Chen J, Yuan YC, Leontiades gi, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol. 2012;46:93-114.

Epstein M, McGrath S, Law F. Proton- pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834-6.

Kim S, Lee H, Park CH, Choong NS, Hyun JL, Jun CP et al. Clinical predictors associated with proton pump inhibitor- induced hypomagnesemia. Am J Ther. 2015;22(1):14-21.

Gommers LMM, Hoenderop JGJ, De Baaij JHF. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol. 2022; 235:e13846.

Li M, Jiang J, Yue L. Functional characterization ofhomo- and heteromeric channel kinases TRPM6 and TRPM7. J Gen Physiol. 2006;127(5):525-37.

Clooney AG, Bernstein CN, Leslie WD, Vagianos K, Sargent M, Laserna-Mendieta EJ et al. A comparison ofthe gut microbiome between long-term users and non-users ofproton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):974-84.

Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC et al. Proton pump in-hibitors Alter specific taxa in the human gastrointestinal micro-biome: a crossover trial. Gastroenterology. 2015;149(4):883-5.

Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740-8.

Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC et al. Proton pump inhibitors alter the composition ofthe gut microbiota. Gut. 2016;65(5):749-56.

Mishiro T, Oka K, Kuroki Y, Takahashi M, Tatsumi K, Saitoh T et al. Oral microbiome alterations of healthy volunteers with proton pump inhibitor. J Gastroenterol Hepatol. 2018;33(5):1059-66.

Bai JP, Hausman E, Lionberger R, Zhang X. Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. Oral Absorption Magnesium Mol Pharm. 2012;9(12):3495-505.

Gommers LMM, Ederveen THA, Van der Wijst J, Overmars-Bos C, Kortman GAM, Boekhorst J et al. Low gut microbiota diversity and dietary magnesium intake are associated with the development of PPI-induced hypomagnesemia. FASEB J. 2019;33(10):11235-46.

Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36(5):405-13.

U.S Food and Drug Administration. Fact sheet: FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm. Accessed on 26 August 2023.

Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740-48.

Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008;69(2):338-41.

Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM. 2010;103(6):387-95.

Skou JC. Preparation from mammallian brain and kidney of the enzyme system involved in active transport of Na ions and K ions Biochim. Biochim Biophys Acta. 1962;58:314-25.

Salaminia S, Sayehmiri F, Angha P, Sayehmiri K, Motedayen M. Evaluating the effect of magnesium supplementation and cardiac arrhythmias after acute coronary syndrome: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2018;18(1):129.

Bolouri A, Mehrabi GHA, Salehi M. Evaluation of the prevalence of ventricular tachyarrhythmia in patients with acute myocardial infarction and serum magnesium in Khatam-Al-Anbia hospital, Zahedan, Iran. Zahedan J Res Med Sci, Tabib-e-Shaegh. 2006;8(2):93-100

Li XQ, Tembe V, Horwitz GM, Bushinsky DA, Favus MJ. Increased intestinal vitamin D receptor in genetic hypercalciuric rats. A cause of intestinal calcium hyperabsorption. J Clin Invest. 1993;91(2):661-7.

National Library of Medicine. Fact sheet: Overview of Calcium- Dietary Reference Intakes for Vitamin D and Calcium; 2010. Available at: https://www.ncbi.nlm.nih.gov/books/NBK56060/#. Accessed 26 Aug 2023.

Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypocalcemia. J Bone Miner Metab. 2009;27:635-42.

Milman S, Epstein EJ. Proton pump inhibitor-induced hypocalcemic seizure in a patient with hypoparathyroidism. Endocr Pract. 2011;17:104-7.